Lacosamid Mylan

Lacosamide, the active ingredient in Lacosamid Mylan, is an anti‑epileptic (sodium channel modifier) presented as an oral dosage form for oral use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamid Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑epileptic that targets focal seizure activity. - Partial‑onset seizures in adults: Reduces seizure frequency as add‑on therapy. - Partial‑onset seizures in children (≥4 years): Provides adjunctive seizure control in pediatric patients. - Focal seizures refractory to other agents: Offers an alternative mechanism of action for patients not responding to standard treatments.

Lacosamide may cause a range of adverse reactions.

Common Side Effects: - Dizziness: Transient sensation of light‑headedness. - Fatigue: Generalized tiredness or lack of energy. - Nausea: Mild to moderate upset stomach. - Diplopia: Blurred or double vision. - Headache: Mild to moderate cranial pain. - Somnolence: Increased sleepiness.

Serious or Rare Side Effects: - Suicidal ideation: Emergence of thoughts of self‑harm. - Severe skin reactions: Including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac conduction abnormalities: PR‑interval prolongation that may lead to arrhythmias. - Severe allergic reactions: Anaphylaxis or angioedema. - Hepatic injury: Elevated liver enzymes or liver dysfunction.

When prescribing Lacosamide, clinicians should consider several safety measures. - Monitor seizure control: Adjust dose under medical supervision to achieve optimal efficacy. - Assess renal function: Dose may need modification in patients with impaired renal clearance. - Check cardiac conduction: Baseline ECG recommended due to potential PR‑interval effects. - Avoid abrupt discontinuation: Taper the medication to prevent seizure worsening. - Store at room temperature: Keep in the original container, protect from moisture and light.

Lacosamide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine): May markedly reduce lacosamide exposure. - Drugs that prolong PR interval (e.g., quinidine): Increase risk of cardiac conduction delay. - Concurrent sodium channel blockers (e.g., phenytoin): May heighten toxicity.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: May require dose adjustments based on therapeutic response. - Oral contraceptives: Lacosamide can diminish hormonal efficacy, necessitating alternative contraception. - Alcohol: Combined use may enhance central nervous system depression and dizziness.